Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM
Original Article from The New England Journal of Medicine — Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Related Articles
Heart Failure
Return to CVD Roadmaps Home Due to the aging population, increase in cardiovascular risk factors and improved survival of cardiovascular conditions, the prevalence of heart…
The Role of Multiple Mutations in Hypertrophic Cardiomyopathy – A New Universe to Discover: Proof of Guiltiness of the Genetic Burden in Worsening Hypertrophic Cardiomyopathy Natural History
Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiovascular diseases, with a prevalence between 1:200 and 1:500, affecting more than 20 million people…
Aetiology and clinical manifestations of patients with non‐dilated left ventricular cardiomyopathy
Click on the article title to read more.
Heart failure risk assessment in patients with hypertrophic cardiomyopathy based on the H2FPEF score
The H2FPEF score in hypertrophic cardiomyopathy. CI, confidence interval; HCM, hypertrophic cardiomyopathy; LV, left ventricular; sPAP, systolic pulmonary artery pressure.
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | NEJM
Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure…
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | NEJM
Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure…
Impact of heart failure hospitalizations on clinical outcomes after mitral transcatheter edge‐to‐edge repair: Results from the EXPAND study
In the EXPAND study, subjects with prior HFH had an increased incidence of all-cause mortality at 1 year. Associations with 1-year HFH after mitral transcatheter edge-to-edge…
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | NEJM
Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure…
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | NEJM
Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure…
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | NEJM
Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure…